DnB Asset Management’s Palvella Therapeutics PVLA Stock Holding History

DnB Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343K	Buy	+2,244	New	+$272K	﹤0.01%	967

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

DnB Asset Management's PVLA Position: Q2 2026 in Review

DnB Asset Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 2,244 shares worth $343K. The stake represents ﹤0.01% of the portfolio and ranks #967 among its holdings.

196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

DnB Asset Management held 2,244 shares of Palvella Therapeutics worth $343K as of Q2 2026.
Palvella Therapeutics was a new DnB Asset Management position in Q2 2026.
Palvella Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #967 holding.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.